MGTX: MeiraGTx Holdings plc Operating Margin

Graphic logo of MeiraGTx Holdings plc (MGTX)

The current operating margin of MeiraGTx Holdings plc (MGTX) is based on the stable operation of its own gene therapy manufacturing plants. The 44.50 metric captures the value of this parameter, demonstrating effective cost management. The development of MeiraGTx Holdings plc (MGTX) relies on correcting genetic defects to treat blindness, while its financial stability depends on clinical trial outcomes and capital expenditure control.

meiragtx.com (MGTX): Return on Sales by Operating Profit from 07/04/2022 to 11/20/2026

MGTX (MeiraGTx): analytical breakdowns and indicator data

- share price and consensus valuation forecast:
Fundamental company valuation:MGTX, MeiraGTx
Core merchandise of meiragtx.com

MeiraGTx Holdings plc (MGTX) is developing a high-tech gene therapy segment characterized by significant capital expenditures. Costs associated with environmental safety and reagent disposal directly impact the calculated remaining funds from sales. The operating margin measures the share of earnings before interest and taxes, reflecting the efficiency of core process management. Low values here often signal an expansion phase. By analyzing the operating margin, an investor performs a real-time assessment of the business's profitability.

Who MeiraGTx Holdings plc competes with

Operating Sales Margin TEM|QGEN - Operating Profitability Margin|Operating Margin IONS|RGEN - Operating Return on Sales|Operating Profitability Avidity RNA|Operating Margin CRISPR Therapeutics Corp CRSP|GeneDx Corp - Operating Margin|Ultragenyx Pharma (RARE) - Operating Sales Margin|beamtx.com (BEAM) - Operating Profitability|SRPT: Operating Profit Ratio|Operating Sales Margin TWST|TXG - Operating Profitability Margin|Operating Margin NTLA|Profitability of Operations Stoke Therapeutics|Operating Profitability BioLife Solutions BLFS|Wave Life Sciences (WVE) - Operating Return on Sales|Maze Therapeutics, Inc. - Operating Margin|Profitability of Operations Sionna Therapeutics, Inc. SION|Prime Medicine Bio (PRME) - Operating Profitability|TSHA: Operating Profit Ratio|Operating Profitability uniQure Pharma|Operating Return on Sales REGENXBIO Inc. RGNX|Operating Profitability Solid Biosciences (SLDB)|Ocugen Corp - Return on Sales by Operating Profit|Operating Profitability Pacific Biosciences PACB|Operating Profit Ratio BNTC (Benitec)|Design Corp - Operating Margin|Rocket Pharmaceuticals - Operating Profit Ratio|Return on Sales by Operating Profit 4D Molecular Therapeutics, Inc.|Operating Return on Sales Lexeo Therapeutics (LXEO)|KRRO (Korro Bio, Inc.) - Operating Margin|Operating Return on Sales Editas EDIT|Operating Margin SLN|ProQR Therapeutics - Return on Sales by Operating Profit|Operating Margin CDXS (Codexis, Inc.)|SGMO: Return on Sales by Operating Profit|Nautilus Biotechnology - Operating Margin|Operating Profit Rate MGX (Metagenomi, Inc)|DTIL: Operating Margin|GBIO: Operating Profit Ratio|Operating Profitability Boundless Bio Inc.|Operating Sales Margin Exicure (XCUR)|Operating Margin IMNN|PHIO (Phio Pharmaceuticals Corp.) - Operating Profit Rate|Mustang Bio, Inc. - Operating Sales Margin|RNAZ - Operating Sales Margin|BNGO: Operating Sales Margin|APDN (Applied DNA Sciences Inc) - Return on Sales by Operating Profit|BLUE (Bluebird Bio) - Operating Sales Margin|ImmunoPrecise Antibodies Ltd - Operating Profit Rate|OMGA (Omega Therapeutics Inc) - Operating Margin|Operating Profitability OMIC|Operating Profitability Regulus Therapeutics Inc. (RGLS)|Operating Sales Margin Syros Pharmaceuticals, Inc. SYRS|Telesis Bio - Operating Sales Margin|Operating Profit Rate TCON|UBX - Operating Profitability